Evan Lippman - May 14, 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Business Development
Signature
/s/ Dov Bergwerk as attorney-in-fact for Evan Lippman
Stock symbol
TEVA
Transactions as of
May 14, 2025
Transactions value $
$0
Form type
4
Date filed
5/19/2025, 04:00 PM
Previous filing
Apr 7, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lippman Evan EVP, Business Development C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Evan Lippman 2025-05-19 0002062834

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +47.4K $0.00 47.4K May 14, 2025 Ordinary Shares 47.4K Direct F1, F2, F3
transaction TEVA Restricted Share Units Award $0 +148K $0.00 148K May 14, 2025 Ordinary Shares 148K Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on May 14, 2025 with 11,841 vesting on each of May 14, 2026, May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F4 Restricted share units were granted on May 14, 2025 with 74,008 vesting on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028.